Eisenmenger Quality Enhancement Research Initiative

Actelion193 enrolled

Overview

Eisenmenger Quality Enhancement Research Initiative (QuERI) is a multi-center, observational, US-based longitudinal program, with enrollment of consecutive Eisenmenger patients who meet enrollment. Patient data will be collected prospectively for three years. Individual physician feedback will be provided on data collected with the purpose of improving the management of patients - quality enhancement research initiative (QuERI) process.

Approximately 200 male and female adult patients with a history of Eisenmenger will be recruited from approximately 50 cardiology practices over a period of 18 months and will be followed up every six months for the period of three years. Consecutive patients in each practice meeting inclusion and exclusion criteria should be considered for the study. Participating sites will be asked to maintain a screening log to identify which inclusion or exclusion criteria was not met thus excluding them from the study.

Study Type

OBSERVATIONAL

Enrollment

193

Conditions

Pulmonary Arterial Hypertension

Interventions

Subjects with diagnosis of Eisenmenger SyndromeOTHER

1. Antibiotic recommendation for SBE prophylaxis and influenza vaccine 2. Contraception counseling, and recommendations regarding avoidance of pregnancy 3. Documentation and prescription of the specific medications: 1. Oxygen 2. Diuretic 3. ASA, Anticoagulant 4. CCB, BB, ACEI, ARB 5. Iron Supplementation 6. Allopurinol 7. PAH specific therapy

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Male and female patients * Diagnosis of Eisenmenger syndrome based on right heart catheterization data * Right to Left intra-cardiac shunting * PAH * Need for comprehensive management according to guidelines and peer-reviewed evidence * Ability and desire to execute the consent for follow up Exclusion Criteria: * Poor mental function, drug, or substance (e.g.,alcohol) abuse, or unstable psychiatric illness, which, in the opinion of the investigator, may interfere with optimal participation in the study * Prior inclusion in this program

Outcomes

Primary Outcomes

Characterization of the clinical course of patients with Eisenmenger Syndrome

The management of Eisenmenger Syndrome patients over the three year registry period will be compared with established national guidelines. In addition, The Minnesota Living with Heart Failure questionnaire (MLHFQ) will be collected.

Time frame: up to 3 years

Secondary Outcomes

Characterization of the demographics of patients with Eisenmenger Syndrome

Time frame: baseline (visit 1) thru end of study (3 years)

Identification of clinical predictors of short-term and long-term outcomes of patients with Eisenmenger Syndrome.

Time frame: baseline (visit 1) thru end of study (3 years)

Characterization of patients treated with PAH-specific medications to patients untreated with PAH-specific medications.

Time frame: baseline (visit 1) thru end of study (3 years)

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.